Tise Suzuki on Muck Rack

Tise Suzuki

As seen in: MDPI
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Tise

Contact Tise, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

A Stem-like Patient-Derived Ovarian Cancer Model of Platinum Resistance Reveals Dissociation of Stemness and Resistance

|
By Tise Suzuki, Ashlyn Bartlett Conant, Yeonkyu Jung, Ryan Bax
| MDPI
All articles published by MDPI are made immediately available worldwide under an open access license. No special permission is required to reuse all or part of the article published by MDPI, including figures and tables. For articles published under an open access Creative Common CC BY license, any part of the article may be reused without permission provided that the original article is clearly cited. For more information, please refer to https://www.mdpi.com/openaccess.
Open in Who Shared View Duplicates (696) Issue with article?

Modeling platinum resistance in a stem-like patient-derived ovarian cancer sample

|
By Tise Suzuki, Ryan Bax, Ashlyn Bartlett Conant, Yeonkyu Jung
| biorxiv.org
Abstract Background Chemoresistance and tumor recurrence remain a significant challenge in ovarian cancer. Particularly in the context of platinum resistance, many mechanisms have been identified, including the activation of cellular processes like epithelial-mesenchymal transition (EMT), which generates cells with stemness characteristics. Current models of platinum resistance are limited or not adequate representations of the heterogeneity of the disease.
Open in Who Shared Issue with article?

Glucocorticoid Receptor Regulates and Interacts with LEDGF/p75 to Promote Docetaxel Resistance in Prostate Cancer Cells

|
By Evelyn S. Sanchez-Hernandez, Pedro Ochoa, Tise Suzuki, Greisha L. Ortiz-Hernandez
| MDPI
1. Introduction Prostate cancer (PCa) is the second most common male cancer and the fifth most common cause of cancer-related death among men worldwide [1,2]. Although localized PCa has an excellent prognosis, the 5-year survival rate for patients with metastatic disease can be as low as 30% [3]. Androgen deprivation therapy (ADT) is initially effective until metastatic castration-resistant PCa (mCRPC), the terminal disease state, develops [4,5].
Open in Who Shared Issue with article?
See all 4 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified